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A B S T R A C T
Introduction: Alzheimer's disease (AD) is the most prevalent neurodegenerative disorder in elderly people.
Existent therapies are directed at alleviating some symptoms, but are not effective in altering the course of the
disease.
Methods: Based on our previous study that showed that an Aβ-interacting small peptide protected against the
toxic effects of amyloid-beta peptide (Aβ), we carried out an array of in silico, in vitro, and in vivo assays to
identify a molecule having neuroprotective properties.
Results: In silico studies showed that the molecule, referred to as M30 (2-Octahydroisoquinolin-2(1H)-yletha-
namine), was able to interact with the Aβ peptide. Additionally, in vitro assays showed that M30 blocked Aβ
aggregation, association to the plasma membrane, synaptotoxicity, intracellular calcium, and cellular toxicity,
while in vivo experiments demonstrated that M30 induced a neuroprotective effect by decreasing the toxicity of
Aβ in the dentate gyrus of the hippocampus and improving the alteration in spatial memory in behavior assays.
Discussion: Therefore, we propose that this new small molecule could be a useful candidate for the additional
development of a treatment against AD since it appears to block multiple steps in the amyloid cascade. Overall,
since there are no drugs that effectively block the progression of AD, this approach represents an innovative
strategy.
Significance: Currently, there is no effective treatment for AD and the expectations to develop an effective
therapy are low. Using in silico, in vitro, and in vivo experiments, we identified a new compound that is able to
inhibit Aβ-induced neurotoxicity, specifically aggregation, association to neurons, synaptic toxicity, calcium
dyshomeostasis and memory impairment induced by Aβ. Because Aβ toxicity is central to AD progression, the
inhibition mediated by this new molecule might be useful as a therapeutic tool.
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In the quest for the development of new pharmacotherapeutics to
treat AD, these compounds ideally should be able to modify its course
by interfering with one of the most toxic agents of the disease, Aβ.
Current treatments are aimed at alleviating some symptoms of the
disease but are not effective in modifying the disease, and patients
continue with progressive cognitive deficits (Salomone et al., 2012).
Thus, the cellular target where Aβ exerts its toxic effect is not known
and prevents the development of an effective treatment. Furthermore, it
is believed that early symptoms of AD, such as confusion and memory
loss, are likely associated to synaptic alterations caused by Aβ oligo-
mers (Shankar et al., 2007).
We previously found that a small peptide derived from an amino
acid sequence of Aβ (GLMVG) interacted with the C terminal region of
Aβ and blocked its aggregation, association, and perforation of the
neuronal membrane, and also prevented changes in intracellular cal-
cium levels and the synaptotoxicity induced by Aβ (Peters et al., 2013).
Based on these findings, we are now searching for a low molecular
weight compound that can interact and inhibit the toxicity of Aβ be-
cause it is the principal toxic agent in AD (Jin et al., 2011; Sandberg
et al., 2010). Using a virtual screening based on the C-terminal region of
Aβ as the “receptor”, we identified a set of small molecules with the
capacity to associate to this region. The most active compound as de-
termined by secondary assays, referred to as M30, was used to perform
a detailed characterization in the present study. To be effective, any
suitable compound must have a number of pharmacokinetic properties
for its use as a drug in the central nervous system. For example, it
should consider Lipinski's rule of five (Lipinski et al., 2001) or Jor-
gensen's rule of three (Jorgensen and Duffy, 2002), have an ability to
cross the blood-brain barrier (Kelder et al., 1999), a potential activity in
the central nervous system (Ajay et al., 1999), and not be extensively
metabolized. Additionally, the filters must be used to select compounds
with an acceptable range to evaluate drug-likeness. In silico methodol-
ogies have already been used to identify molecules that inhibit pro-
cesses of different diseases (Grover et al., 2014; Veeramachaneni et al.,
2015). Here we describe the first compound we found that interferes
with several toxic steps in the amyloid cascade (Fig. 1), the molecule
M30 (2-Octahydroisoquinolin-2(1H)-ylethanamine).
2. Results
The experimental approach included the sequential use of in silico,
in vitro and in vivo studies. The goal was to identify and characterize a
novel small molecule capable of antagonizing the toxicity of Aβ.
2.1. In silico
To circumvent the disadvantages of using peptides in pharma-
cotherapy, we wanted to identify low molecular weight compounds that
can interact with the same region where GLMVG blocks Aβ toxicity and
could be used in pharmacotherapy (Peters et al., 2013). Initially, the
docking simulation with the Aβ monomer grid centered on the C-
terminal region (Aβ-CT) and the library of filtered molecules was per-
formed in the SP precision of Glide. Once the docking with the Aβ
monomer was completed, 2,425,934 complexes equivalent to 89.7% of
the filtered molecules were obtained. The remaining 279,137 molecules
(10.3%) were unable to generate stable poses with the interaction grid.
Subsequently, all the complexes were ordered according to the docking
score value, and ΔGbind (MM-GBSA) was calculated for the best 1000
molecules. The combination of the in silico results with preliminary
primary assays allowed us to select a single molecule (M30, 2-Octa-
hydroisoquinolin-2(1H)-ylethanamine (Fig. 2A)) that showed the best
protective activity in all performed assays. The data showed that this
molecule interacted stably with the C-terminal portion of the Aβ
monomer presenting a docking score of −6.096 (Fig. 2B). A more
detailed analysis of the interface revealed that between M30 and the Aβ
monomer 2 hydrogen bonds were formed between the NH groups of the
molecule and the carboxyl and hydroxyl groups of the main chains of
amino acids valine 39 and alanine 42, respectively. A salt bridge be-
tween M30 and alanine 42 was also detected in the interaction
(Fig. 2C). For the selected molecule, a second protein-ligand docking
was performed using a grid that evaluated the remaining Aβ monomer,
especially the central loop that was associated with the folding changes
in the aggregation process (Aβ-LP). M30 was able to interact favorably
with the Aβmonomer in the region near the hinge generating a docking
score of −5256 and involving amino acids valine 18, alanine 21,
Fig. 1. Scheme of the experimental approach used to identify novel anti AD
drugs. In silico: The blue box represents the grid used to identify small molecules
interacting with the C-terminal region of Aβ1–42. These molecules were selected
from the ZINC database using a set of filters to identify those having better CNS
pharmacological properties. In vitro: We evaluated selected molecules on Aβ
aggregation, association, perforation of the membrane, and synaptotoxicity in
hippocampal neurons. Aβ is represented as pale blue circles and the molecules
as purple triangles (M). The M30 compound was the most active in inhibiting
the toxic effects of Aβ in most primary assays and exhibited good ADME
parameters. In vivo: Stereotaxic injection of Aβ into the mouse dentate gyrus
was used to evaluate neuronal toxicity in vivo after 2 weeks post-surgery.
Moreover, a memory-learning test, the Barnes Maze, was used to assess the
protective effects of the molecules in the mice. (For interpretation of the re-
ferences to colour in this figure legend, the reader is referred to the web version
of this article.)
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glutamic acid 22, glycine 25 and serine 26 in the binding site (Fig. 2D).
In the interface of this second binding site, we detected the formation of
two hydrogen bonds and a salt bridge with glutamic acid 22 of Aβ
(Fig. 2D). Both complexes had favorable ΔGbind values (−26.428 kcal/
mol C-terminal grid; −31.687 kcal/mol central grid) which, together
with the aforementioned, confirmed an in silico interaction between
M30 and Aβ. These structural and energetic properties add to the
previously calculated ADME parameters, known as the critical phar-
macokinetic hurdles (absorption, distribution, metabolism, elimina-
tion) that a drug must address before being approved by the FDA for
clinical use (Supplementary Table 1), that indicated that M30 is a po-
tential candidate to inhibit the toxic effects of the Aβ peptide.
2.2. Molecular dynamics analysis between Aβ and M30
To improve the predictions for binding of M30 to the Aβ peptide, we
performed molecular dynamics simulations on Aβ, and the complexes
Aβ-M30/CT and Aβ-M30/LP, in explicit water molecules over 1 μs. The
Aβ peptide was divided into five regions for the analysis: 1) N-terminal
(Asp1-Lys16), 2) central hydrophobic core (Leu17-Ala21), 3) loop re-
gion (Glu22-Lys28), 4) second hydrophobic core (Phe29-Met35), and 5)
C-terminal region (Val36-Ala42). Although M30 was initially located in
the docking simulation in the LP and the CT poses, this was able to
closely interact with the entire Aβ peptide (Fig. 3A). Analysis of the
secondary structure along the simulations showed that Aβ had
~10.22% of β-sheet, ~13.50% of helix, ~20.52% of turns
and ~ 55.75% of coils (Supplementary Table 2, Fig. 3B). The averaged
helical content was reduced to ~8.72% and ~ 10.86% in the case of
Aβ–M30 (LP) and Aβ-M30 (CT), respectively. Additionally, a reduction
in the content of β-sheet to 7.03% was detected in the Aβ-M30 (LP)
complex. The decrease in the β-sheet content in the case of Aβ–M30
(LP) can be associated to prevention of Aβ self-assembly and aggrega-
tion, where the propensity of β-sheet formation at region Leu17-Met35
changed from 11.2% to 6.5% in the presence of M30 (Fig. 3B). These
results indicate that M30 was able to modify the secondary structure of
Aβ, with a tendency to reduce the formation of β-sheet structures. This
was also accompanied by a decrease in intramolecular interactions (Fig.
S2). Taken together, the in silico results indicate that M30 is able to
interact and modify the structural properties of Aβ reducing its toxicity.
2.3. Aβ structure and aggregation
It is well known that Aβ aggregation forms β-sheet structures
(O'Nuallain et al., 2010; Riek and Eisenberg, 2016). Circular dichroism
experiments confirmed that after aggregation, Aβ was chiefly composed
of β-sheet structures (Fig. 4A). As we showed with in silico analysis,
M30 was able to affect Aβ, and this likely molecular interaction resulted
in changes in Aβ aggregation and alteration in the secondary structure
of Aβ oligomers or fibers. Indeed, M30 was able to reduce the β-sheet
content of 1 μM Aβ after co-incubation with two different concentra-
tions (5 and 10 μM) (Fig. 4A). To confirm that the changes observed in
Aβ spectra were not due to peptide precipitation, we monitored the
protein present in the cuvette by absorbance, before and after adding
M30, and found no significant changes between the samples of Aβ with
and without M30. This suggests that the observed change in circular
dichroism was related to a change in the secondary structure of the
peptide. From this data, we concluded that the main change in Aβ
structure was from antiparallel β-sheets to other structures, and no
alpha helix structures were found in all tested conditions (Table sup-
plementary 3).
The change in the secondary structure of Aβ could be related to
alterations in the aggregation by M30. Therefore, we next examined if
M30 was able to alter the aggregation of Aβ oligomers measured as the
change in absorbance (ΔAbs/Abstime0). The data obtained with this
approach showed that Aβ aggregation (32 μM; red) was inhibited in the
presence of M30 (160 μM; blue) (Fig. 4B). To maintain the 1:5 Aβ:M30
Fig. 2. Docking between M30 and Aβ monomer. (A) Chemical structure of M30. (B) M30-Aβ complexes generated by molecular docking for the C-terminal (a) and
the loop regions (b). The zooms shown on the right side correspond to the side chains of the amino acids involved and are represented as lines. (C, D) Schematic
representation of M30 interactions with Aβ. Predictions were generated with the structure obtained by PDB 1IYT. Ligand-interaction diagram of complexes between
M30 and Aβ, where (C) corresponds to the C-terminal grid, while (D) to the central grid. The legend of the schemes is common for both interaction grids.
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ratio used in the CD study, the corresponding concentration of M30 was
160 μM.
2.4. Inhibition of Aβ association to neuronal membranes in the presence of
M30
Next, we evaluated if M30 was able to decrease Aβ association to
PC12 cells and hippocampal neurons (Fig. 5, and S3). To assess this, we
first performed a dot blot assay to determine the level of association of
Aβ with PC12 cells for a 60 min treatment (5 μM), in the absence and
presence of 25 μM M30 (Fig. 5A). Quantification of the data obtained
from 6 different experiments showed a significant reduction in the as-
sociation of Aβ (Fig. 5B, **p < .01). Moreover, western blot analysis
also showed a similar reduction in Aβ association to neurons after 1 h
incubation, while another molecule (M29) did not show this effect (Fig.
S3). This reduction of Aβ association was confirmed with studies in
hippocampal neurons. Using confocal microscopy and fluorescent Aβ,
we found that the association of Aβ-6-carboxyfluorescein (1 μM Aβ-
FAM, green) was reduced in the presence of M30 (Fig. 5C). For these
analyses, the neurons were identified using an antibody that recognized
MAP2, a neuronal protein (red). The data show that the intensity and
the number of Aβ punctas associated with the neurons was reduced by
5 μM M30 (Fig. 5 D,E, p < .05.; *** P < .001, n = 4). Specifically,
there was a significant reduction in these two parameters in primary
processes (length 20 μm) when the neurons were treated with the
compound.
2.5. M30 inhibited the increase in intracellular calcium induced by Aβ
oligomers
Our working model for neurotoxicity involves an association of Aβ
to the membrane that causes membrane disruption and is followed by
an increase in intracellular calcium and synaptotoxicity (Parodi et al.,
2010; Peters et al., 2016; Peters et al., 2013). Therefore, we examined if
M30 was able to interfere with the increase in intracellular calcium
induced by application of Aβ (5 μM) to PC12 cells (Fig. 6). Compared
with ionomycin (10 μM), a well-known membrane permeabilizing
compound, we found that Aβ, although to a lower level, also increased
the level of intracellular calcium, as monitored by the change in Fluo-8
fluorescence (Fig. 6A). Application of M30 was able to attenuate the
effect of Aβ during the time course of the experiment (Fig. 6B), and the
bar graph shows the changes at 25 min of application in the absence
and presence of M30 (Fig. 6C, p < .001, n = 3).
2.6. M30 inhibited the synaptoxicity induced by Aβ oligomers in
hippocampal neurons
It was previously shown that Aβ oligomers are synaptotoxic, as re-
flected by a reduction in the levels of the synaptic vesicle protein 2
(SV2) and the synaptic activity of the neurons (Peters et al., 2015;
Peters et al., 2013). Here, we used western blot and im-
munocytochemistry analyses to evaluate SV2 levels in hippocampal
neurons. The results obtained by western blot show that treatment with
Aβ (1 μM) reduced the level of SV2 to about 50% of control and that
M30 (5 μM) was able to block this Aβ-induced synaptotoxicity (Fig. 7A
and B, p < .005, n = 4). Furthermore, confocal microscopy confirmed
that M30 decreased the reduction in the SV2 signal in presence of Aβ
(Fig. 7C), as measured by intensity (Fig. 7D) and number of punctas
(Fig. 7E) in the primary processes of these neurons. The synaptic al-
terations produced by long-term treatment of hippocampal neurons
with Aβ is accompanied by a reduced number of spontaneous in-
tracellular calcium transients (Peters et al., 2015). Therefore, we
measured the frequency of calcium transients after chronic treatments
with Aβ in hippocampal neurons (Fig. 7F) finding that Aβ decreased the
frequency and that M30 blocked this synaptotoxic effect (Fig. 7G). The
data also showed that M30 did not cause any effect on its own in
spontaneous calcium transients, reflecting unaltered synaptic functions.
Moreover, to further evaluate if M30 antagonized Aβ effects, we treated
hippocampal neurons with Aβ (1 μM) in the presence or absence of
1 μM M30 and recorded the total synaptic activity using voltage clamp
(Fig. 7H). Interestingly, and in agreement with the effects on frequency
of calcium transients, M30 blocked the decrease in synaptic transmis-
sion after exposure of neurons to Aβ (Fig. 7I). Once again, the com-
pound alone did not have any effect altering neurotransmission.
Fig. 3. Molecular dynamics show the distance distribution between M30 and various regions of Aβ-M30(LP) and Aβ-M30(CT). (A) The Aβ sequence was divided into
five regions colored according to the following order: black line, N-terminal (NT, aa 1–16); yellow line, central hydrophobic core (CHC, 17–21); red line, loop region
(LP, 22–28); green line, second hydrophobic core (SHC, 29–35); and blue line, C-terminal (CT, 36–42). The vertical red dotted line at 10 Å represents contacts
between Aβ and M30. (B) Averaged per-residue secondary structure contents for Aβ, Aβ-M30(LP) and Aβ-M30(CT) calculated by DSSP. (For interpretation of the
references to colour in this figure legend, the reader is referred to the web version of this article.)
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2.7. Effect of M30 on mitochondrial function and cellular viability toxicity
induced by Aβ
To evaluate if M30 inhibited the Aβ induced cytotoxicity after
chronic treatment, we assayed mitochondrial function using an MTT
assay together with cell viability using the live/dead assay. After a 24 h
treatment with Aβ alone (1 μM), the MTT (3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide) assay showed a significant reduction
in mitochondrial function, an effect that was significantly attenuated by
co-treatment with M30 (5 μM, ***p < .001, n = 6). M30 by itself did
not alter mitochondrial function, and FCCP, a mitochondrial oxidative
phosphorylation uncoupler, decreased mitochondrial status to less than
20% of control (Fig. 8A). The live/dead assay showed that hippocampal
neuron viability was reduced to ≈60% with long exposures to Aβ
(96 h). The cytotoxic effect of the peptide was blocked by increasing
concentrations (1–50 μM) of M30 (Fig. 8B). Interestingly, M30 was not
able to block the toxicity induced by FCCP, showing a degree of spe-
cificity for protection only against Aβ under the experimental condi-
tions (Fig. 8C). The data also showed that high concentrations of M30
(25–50 μM) did not alter cellular viability (Fig. 8D). Finally, we de-
termined an IC50 for M30 of 680 ± 9 nM to block the toxicity of Aβ
(Fig. 8E).
2.8. Neuronal death and memory impairment was antagonized by M30 in
vivo
After determining that M30 interacted in silico with Aβ and pro-
tected the synapsis in in vitro experiments, it was necessary to examine
if the compound was also effective in in vivo studies. It was previously
reported that direct infusion of oligomeric Aβ into the brain of wild-
type mice provides a rapid approach that replicates several neuronal
death aspects related to amyloidopathy (Jean, 2015) (Baleriola et al.,
2014). In agreement, 2 weeks after the stereotaxic injection of Aβ into
the dentate gyrus (DG) of the mouse hippocampus (Fig. 9 A-C), a de-
crease in DAPI-positive staining was found (Fig. 9D,E). After injection
of Aβ-FAM into the left hemisphere, and Aβ-FAM plus M30 into the
right hemisphere, the results showed a reduction in the Aβ-FAM signal
into the right hemisphere (with M30) after 2 weeks (Fig. 9F and S4).
Analysis of DAPI-positive cells in the hemisphere injected with
Aβ + M30 showed a decrease in cell death induced by Aβ (Fig. 9G-I).
Finally, we performed the Barnes Maze assay, a spatial memory test
(Webster et al., 2014), to examine if mice injected with Aβ plus M30
have less impairment than those injected with Aβ alone (Fig. 10A). The
data showed that the mice that received the administration of Aβ plus
M30 in the DG showed better spatial learning after 1 week post-injec-
tion (Fig. 10B). The data shows that the percentage of animals reaching
the exit within the 3 min time frame of the assay was significantly
higher in those injected with Aβ + M30 than in Aβ alone, showing
similar values with the control group (Fig. 10C). Additionally, the la-
tency, or time that the mice took to reach the exit, was higher in the
mice injected with Aβ than control and Aβ + M30 animals (Fig. 10D).
3. Discussion
3.1. Rationale and justification for the use of small molecular weight
molecules
The global increase in the aging population is resulting in more
cases of Alzheimer's disease (AD), increasing the social and economic
burdens associated to this disorder. For the last 30–40 years, the high
prevalence and lack of effective therapies to treat AD have led scientists
to search for several potential targets that can block the neurotoxic
effects of Aβ. Given the high complexity of the pathophysiology of AD
and our limited knowledge about the biological basis of the disease, it
has been difficult to develop a small-molecule therapy that can reliably
prevent and/or treat this disease. The principal chemical entities de-
scribed to date correspond to inhibitors of Aβ oligomerization, secretase
inhibitors that process APP, vaccines that neutralize Aβ, and trace metal
chelators (Carreiras et al., 2013; De Strooper and Chavez Gutierrez,
2015; Trippier et al., 2013). They all have limited symptomatic effects,
but none show the ability to modify the course of AD (Salomone et al.,
2012).
In a previous study, we identified a small peptide derived from the
C-terminal region of Aβ that interfered with a myriad of toxic effects
induced by Aβ (Peters et al., 2013). Nevertheless, although peptide-
based pharmacotherapies have been used for some time (Banting et al.,
1922), there are limitations in their use. For example, peptidases and
excretory mechanisms decrease the half-life of many peptidergic hor-
mones (Lau and Dunn, 2018). Likewise, the availability of peptidergic
compounds is reduced by enzymes in the gastrointestinal tract that
cleave peptidic bonds, and the high polarity and molecular weight limit
intestinal permeability (Lau and Dunn, 2018). Injectable formulations,
on the other hand, reduce patient compliance in chronic therapy. Small
molecules are generally more suitable for oral delivery and easier to
manufacture than peptides, and additionally new high-throughput
screening (HTS) technologies are shifting the direction towards small
molecules that target peptide-related receptors (Lau and Dunn, 2018).
Small molecules can also be useful to interfere with Aβ oligomers be-
cause, unlike monomeric Aβ which does not have a defined structure,
A
Wavelength (nm)









A  + M30 5 µM
A  + M30 10 µM
B
Fig. 4. The β-sheet structure of Aβ was altered by M30. (A) Circular dichroism
spectra of 1 μM Aβ aggregated alone and in the presence of 5 μM and
10 μM M30 for 24 h at 4 °C. The control condition demonstrated the β-sheet
structure of Aβ (blue line). Co-incubation with 5 μM (red line) and 10 μM M30
(green line) showed a significant change in β-sheet secondary structure of the
peptide. (B) Absorbance measurements showing the aggregation curve of Aβ
oligomers (red, 32 μM) after incubation at 37 °C for 16 h, with or without M30
(160 μM). The assay was started with pre-aggregated oligomers and the data is
represented as the normalization of ΔAbs/Abs0. The control is the vehicle alone.
The data of Aβ with and without M30 displayed p < .001 for most points. (For
interpretation of the references to colour in this figure legend, the reader is
referred to the web version of this article.)
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they are highly structured and have hydrophobic pockets that can be
easily tagged by small molecules such as M30 (Autiero et al., 2013).
With this goal in mind, we have characterized a compound having
multiple effects on the amyloid cascade such as aggregation, associa-
tion, synaptotoxicity, intracellular calcium dyshomeostasis and beha-
vioral impairments.
3.2. Identification of a small molecule derived from an inhibitory
pentapeptide
A previous study showed that a small peptide (GLMVG) interacted
with Aβ and inhibited several steps in the amyloid cascade (Peters
et al., 2013). The present docking and molecular dynamics results
strongly suggest that M30 interacts with the whole peptide molecule
resulting in a reduction in β-sheet content in the Aβ peptide. Previous
data with solid-state NMR revealed that residues from 17 to 35 con-
tributed to the β-sheet formation important for aggregation (Colvin
et al., 2016; Tycko, 2011). Interestingly, the β-sheet content from Aβ
and Aβ–M30(CT) were consistent with the experimental β-sheet con-
tent calculated by NMR and CD studies (Bitan et al., 2003; Huang et al.,
2000; Ono et al., 2009) that showed that the experimental β-sheet
content (15–25%) was greater than what we found for Aβ–M30(LP).
Beta sheet formation is a product of two types of forces: a) hydrophobic
contacts between the central hydrophobic and the second hydrophobic
regions and interactions between the C-terminal and the N-terminal
regions, and b) formation of more stable salt-bridges between As-
p23(Glu22) and Lys28 residues. The hydrophobic contacts and salt-
bridge formations play a significant role in the formation of Aβ struc-
tures with an increased content in β-sheets, which promotes aggrega-
tion. Interestingly, M30 binding to Aβ reduced the population of the
Asp23-Lys28 and Glu22-Lys28 salt bridges and altered contacts be-
tween the central hydrophobic and the second hydrophobic regions, as
well as between the C-terminal and the N-terminal regions. Hence, the
break-up of the contacts and the destabilization of the salt bridges are
main causes for diminishing the β-sheet content and preventing Aβ
aggregation, in agreement with experimental observations. These re-
sults indicate that M30 was able to modify the secondary structure of
Aβ, with a tendency to reduce the formation of β-sheet structures.
Taken together, the in silico results suggest that M30 is able to interact
and modify the structural properties of Aβ reducing its toxicity.
Nevertheless, future binding studies will be necessary to confirm our
conclusions that are based on in silico results.
3.3. Biological evidence supporting an inhibitory effect of M30 on Aβ
toxicity
The results showed that M30 blocked the aggregation of Aβ, which
is in accordance with the effect of a small molecule in altering the β-
sheet structure of Aβ. This could be the basis for neuroprotective effects
of M30 in blocking Aβ toxicity since previous work showed that β-sheet
oligomers are the most toxic species of Aβ (Guivernau et al., 2016;
Sakono and Zako, 2010). In fact, M30 decreased the association of Aβ
with PC12 cells and hippocampal primary neurons, and in vivo, reduced
the acute increase in intracellular calcium induced by Aβ (Fig. 7) that
leads to vesicular depletion after chronic Aβ exposure (Parodi et al.,
2010; Sepulveda et al., 2010). The capacity of M30 to block several
steps of the amyloid cascade was noteworthy. For example, it prevented
the decrease in synaptic protein SV2, calcium transients and synaptic
neurotransmission. Thus, the synaptotoxic effect of Aβ application was
blocked with M30, demonstrating its multi-level blocking properties.
Stereotaxic injection of Aβ into the brain provides an in vivo model
of amyloidosis, replicating in only a few weeks the neuronal death
commonly found in AD (Baleriola et al., 2014; Jean, 2015). Injection of
Aβ allowed us to increase its levels in a spatial and temporal fashion
obtaining results for neuronal death and memory impairment by Aβ. On
the other hand, transgenic mice models require long-term treatment
(several months). M30 decreased cell death and Aβ association at the
site of injection suggesting that it could be of value for additional
screening of compounds with the ability to interfere with the toxic ef-
fects of Aβ. The results of our behavioral experiments confirmed that
Aβ injections into the DG decreased spatial memory and learning and
that this behavior was reverted by M30.
Finally, we believe that the results of this study are significant since
currently there are no active compounds with good efficacy to treat AD.
Therefore, the use of small molecules like the one described here that is
directed against the main toxic biochemical component of the disease
Fig. 5. M30 reduced Aβ association to PC12 cells and neurons. (A) Dot blot obtained from PC12 culture lysates that show Aβ (1 h, 5 μM) association in the absence or
presence of M30 (25 μM). (B) Quantification of Aβ association to PC 12 cells from A. n = 6 (C) The confocal microscopy images were obtained in hippocampal
neurons treated for 60 min with 1 μM Aβ-FAM (green punctae) in absence and presence of M30. To identify the Aβ associated to the neurons, immunofluorescence
with MAP2 (red) was used. (D, E) Quantification of Aβ puncta number per 20 μm of the neuronal primary process and fluorescence intensity. Data obtained in Aβ
from 43 primary processes (20 neurons) and in Aβ + M30 from 17 primary processes (10 neurons). *p < .5; **p < .01; ***p < .001. (For interpretation of the
references to colour in this figure legend, the reader is referred to the web version of this article.)
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opens new possibilities for the future development of treatments in the
fight against Alzheimer's disease.
4. Materials and methods
4.1. Cell cultures
All animals were handled in strict accordance with NIH guidelines
and approved by the Ethics Committee of the Universidad de
Concepción (Concepción, Chile). Primary cultures of rat hippocampal
neurons were obtained from 18-day pregnant Sprague-Dawley rats and
maintained for 10–14 days in vitro (DIV) as previously described
(Aguayo and Pancetti, 1994). Briefly, the neuronal feeding medium
consisted of 90% minimal essential medium (MEM; BRL Technologies,
Rockville, MD), 5% heat-inactivated equine serum, 5% fetal bovine
serum, and a mixture of nutrient supplements. Cells were maintained
with 5% CO2 at 37 °C.
PC12 cell lines (ATCC, Manassas, VA, USA) were cultured as pre-
viously described (Saez-Orellana et al., 2018). Briefly, the cells were
cultured in DMEM with 5% fetal bovine serum, 100 U/ml penicillin,
100 μg/ml streptomycin, 2 mM L-glutamine, and incubated under
standard conditions (37 °C, 5% CO2) until 80% of confluence was
achieved. The cells were plated at a concentration of 50,000 cells/well.
4.2. Aβ aggregation
Human Aβ1–42 labeled with FAM (green fluorescence) at its N-ter-
minus, and unlabeled peptides were purchased from AnaSpec (CA,
USA), and Aβ was purchased from GenicBio (China). The preparation
and storage were performed as previously reported by our laboratory
(Peters et al., 2016). Briefly, Aβ1–42 was dissolved in hexa-
fluoroisopropanol (HFIP), aliquoted, evaporated at room temperature
and stored at −20 °C. To prepare the Aβ oligomers (80 μM), ultrapure
water was added to the aliquots, and after 10–20 min incubation at
room temperature the samples were stirred at 500 rpm using a Teflon-
coated micro-stir bar for 24–48 h at room temperature (~22 °C) to form
Aβ oligomers which were used immediately. The presence of Aβ oli-
gomers in the preparation was checked by a silver stain gel that showed
abundant species between 17 and 50 kDa (data not shown). In addition,
transmission electron microscopy showed smaller-structured oligomers
and the absence of fibers which readily appeared after longer incuba-
tions at 37 °C (Peters et al., 2016).
4.3. Aβ aggregation assay
The Aβ oligomers (32 μM) were incubated with and without the
molecule (160 μM) in a 96 well plate for 20 h at 37 °C. Measurements
were obtained every 2 min in a Novostar multi-reader (Labtech) with an
absorbance filter of 482 nm, and data were integrated and analyzed
with the Novostar software.
4.3.1. Circular dichroism of Aβ
Spectra of Aβ samples aggregated alone and with M30 were ob-
tained on a Jasco J-815 spectrophotometer (Jasco, Japan) with a
100 nm/min scan speed. The data were recorded over 250 to 190 nm
wavelengths at room temperature with a 10 mm length quartz cell.
Aβ42 (1 μM) was aggregated with 0, 5, and 10 μM M30 to maintain a
1:1 and 1:5 ratio, respectively. The resulting spectra were corrected by
subtracting the solvent background. Processed data were smoothed for
better presentation. We measured the protein content in the cuvette
before and after adding M30 to be sure that Aβ had not precipitated in
solution when adding M30 using the colorimetric Protein Assay Kit BCA
(Pierce). No noticeable changes were detected between the Aβ sample
with and without M30 at both tested concentrations (5 and 10 μM).
Because both Aβ and M30 have a similar absorbance in solution, this
result indicates that the peptide is present in the cuvette and the ob-
served change in the circular dichroism is related to a change in the
secondary structure of the peptide due to the action of M30.
4.4. M30 molecule preparation
The molecule 2-Octahydroisoquinolin-2(1H)-ylethanamine (Matrix
Scientific, USA) was dissolved in dimethyl sulfoxide (DMSO) to a final
concentration of 10 mM, and aliquots were stored at −20 °C until use.
For lower stock concentration, M30 was dissolved in ultrapure water or
saline.
4.5. Structure-based virtual screening
A set of approximately 13,200,000 molecules belonging to the
“Clean drug-like” subgroup were obtained from the ZINC database
(UCSF, USA) and prepared to generate their minimized energy con-
formations and protonated states corresponding to pH 7 ± 0.2. Prior
to docking simulations, ADME properties for all molecules were cal-
culated with QuikProp (Schrödinger, LLC, NY, 2016) and then filtered
according to the following requirements: no transgressions in Lipinski's
rule of five or in Jorgensen's rule of three (Jorgensen and Duffy, 2002;
Lipinski et al., 2001), ability to cross the blood-brain barrier
[PlogBB> − 1] (Kelder et al., 1999), potential activity in the central
nervous system [CNS ≥0] (Ajay et al., 1999), and not extensively
Fig. 6. M30 attenuated the increase in intracellular Ca2+ induced by Aβ in
PC12 cells. (A) The data show changes in the intensity of fluorescence for fluo-8
indicator under control conditions (vehicle), in presence of Aβ (5 μM) and io-
nomycin (10 μM, as positive control). (B) The data shows changes in in-
tracellular calcium after treatment with Aβ (5 μM) alone or with M30 (25 μM).
(C) The data represent values of fluorescence derived from data in panel B,
measured at 25 min after the application of Aβ alone or with M30.
***p < .001, n = 3.
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metabolized in the body [#metab< 4]. Subsequently, we performed a
massive docking protein-ligand with Glide using the selected molecules
and the interaction grid created on the C-terminal (CT) of the Aβ
monomer surface and centered on amino acids 32I, 35MV36, 39VVIA42 as
centroid (Schrödinger, LLC, NY, 2016). Docking simulations, using 1IYT
Aβ structure, were performed with the SP option of the Glide software
that corresponds to the standard precision docking algorithm and in a
second instance, they were refined using the XP algorithm which has a
higher precision. Analysis of the Aβ/molecule interface by the same
software including structural and energetic parameters generated a
docking score used to rank all tested molecules. Additionally, an energy
calculation was done using MM-GBSA for the best-ranked complexes
with Prime software (Schrödinger, LLC, NY, 2016) to predict a theo-
retical ΔGbind. Taken together, the docking score and ΔGbind improved
the description of the interaction between Aβ and the small molecules.
Finally, selected molecules were evaluated in a second docking using a
larger interaction grid including the central loop region (LP) to detect
additional interaction sites on the surface of the Aβ monomer.
4.6. Molecular dynamics simulations
The M30 ligand was optimized at the Hatree-Fock/6-31G* level of
theory using the Gaussian09 software. The generalized amber force
field parameters of the ligand were obtained with the Antechamber
program using partial charges from quantum chemical calculation
based on the restrained electrostatic potential (RESP). Two poses of the
M30 molecule obtained from the structure-based virtual screening
procedure were used to generate two peptide systems: Aβ-M30(CT) and
Aβ-M30(LP). The Aβ, Aβ-M30(CT), and Aβ-M30(LP) structures were
solvated with approximately 13,600 TIP3P water in 500,070 Å3 volume
of the cubic box separately. Five independent molecular dynamic tra-
jectories simulations were generated for each of the three peptide re-
gions. The force field ff99SB-ILDN, which exhibits considerably better
agreement with the NMR data, was used in our simulations [Lindorff-
Larsen et al., 2010, https://doi.org/10.1002/prot.22711]. The energy
of each system was initially minimized by using 500 steps of the stee-
pest descent minimization method, subsequently followed by 500 steps
of the conjugate gradient method with the peptide being constrained by
using a 500 kcal/mol harmonic potential. The system was further
minimized by using 1000 steps of the steepest descent followed by 1500
steps of the conjugate gradient minimization method without restraints.
Once energy minimization was done, the system was equilibrated using
two steps: first, an NVT (constant temperature) ensemble was employed
for 20 ps, and the temperature was gradually increased from 0 to 300 K;
second, NPT (constant pressure) ensemble was applied for 200 ps to
reach the correct water density at 1 atm pressure. Each trajectory was a
production run for 1000 ns using an NPT ensemble. Production data
were collected every 20 ps. The length of all bonds was constrained by
the SHAKE algorithm. The Particle Mesh Ewald (PME) method was used
for the long-range electrostatic interactions, and a 10 Å cutoff range
was used to calculate the electrostatic interactions. The Langevin
thermostat was used to control the temperature. In overall, a total of
5000 ns (5 trajectories×1000 ns) simulation of Aβ1–42, Aβ1–42-
M30(CT) and Aβ1–42-M30(LP) were used. All of the analysis of the
present work was carried out from 200 ns to 1000 ns. The secondary
structure per residue of the peptide was calculated using the DSSP
Fig. 7. M30 inhibited the synaptic toxicity induced by Aβ. (A) Western blots for SV2 after 24 h of incubation with Aβ (1 μM) and M30 (5 μM). The western blot for β-
actin was used as a control for the amount of SV2 loaded. (B) SV2 normalized immunoreactivity from panel A taking the control value as 100%, n= 4. (C) Confocal
microscopy shows SV2 (red) and MAP2 (green) after 24-h treatment with Aβ (1 μM) and M30 (5 μM). (D, E) SV2 fluorescence intensity and the number of punctas in
primary processes per 20 μm from panel C. Number of primary processes quantified in Control (31 processes from/20 neurons), Aβ (24/14 neurons), Aβ+M30 (13/
9 neurons), M30 (14/9 neurons). (F) M30 blocked the decrease in calcium transients induced by chronic application of Aβ (1 μM, 24 h) to hippocampal neurons. (G)
Frequency of calcium transients from panel F. H) Representative traces of synaptic neurotransmission in hippocampal neurons after 48 h application of extracellular
Aβ oligomers (1 μM), in the presence or absence of M30 (1 μM). I) Quantification of synaptic transmission from panel H, showing that the decrease in synaptic
transmission induced by Aβ was blocked by M30. * p < .05, ** p < .01. *** p < .001. (For interpretation of the references to colour in this figure legend, the
reader is referred to the web version of this article.)
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program. The root-mean-square deviation (RMSD) of the Cα atoms as a
function of time is shown in Fig. S1 (Fig. S1). The RMSD values were
stable for all peptides after 200 ns of simulation. After this time, the
RMSD of all the systems fluctuated around its equilibrium value. We
calculated the distance between the center of mass of M30 and different
regions of the peptides using the ‘distance’ program in Amber. Salt-
bridges were identified between positively charged amino acids Arg5,
Lys16, and Lys28, and negatively charged amino acids Asp1, Glu3,
Asp7, Glu11, Glu22, and Asp23. We considered a salt bridge between
two charged residues when the distance between two specific atoms
was below 4.5 Å. The salt bridges between positively and negatively






= ≤S if r1 0i j i j, ,
= >S if r0 0i j i j, ,
= − −r r r d| |i j i j, 0
where i and j relate to Nζ (Lys), Nη (Arg), Cγ (Asp), and Cδ (Glu). d0 is
the distance between atoms i and j. The value of d0 was 4.5 Å. Mole-
cular dynamics simulations were performed using the Amber16
package.
4.7. Calcium imaging
Hippocampal neurons were loaded with Fluo-8 AM (1 μM in
pluronic acid/DMSO, Abcam, USA) for 30 min at 37 °C and then wa-
shed twice with external solution (in mM: 150 NaCl, 5.4 KCl, 2.0 CaCl2,
1.0 MgCl2, 10 glucose, and 10 HEPES (pH 7.4)). Cells were mounted in
a perfusion chamber that was placed on the stage of an inverted
fluorescent microscope (Eclipse TE, Nikon) equipped with a xenon lamp
and a 40× objective (22–24 °C) and subsequently illuminated for
200 ms using a computer-controlled Lambda 10–2 filter wheel (Sutter
Instruments) and regions of interest were simultaneously selected on
neuronal somata containing Fluo-8 fluorescence (absorption 490 nm
and emission 514 nm) in a field having usually more than 10 cells. For
transient recordings, images were collected at 1 s intervals during a
continuous 200-s period of recording with a 12-bit cooled SensiCam
camera (PCO, Germany). Finally, calcium transients were acquired and
analyzed offline with Axon Instruments Workbench 2.2 software.
For long-term recordings in PC12 cells, a multi-reader plate
(Novostar, Labtech) in fluorescence mode was used, measuring the total
fluorescence of each well every 2 min for 10 min at 37 °C and after that,
Aβ oligomers (1 μM) with or without M30 (5 μM) were injected and
data was recorded for 40 min.
4.8. MTT reduction assay
PC12 cells were incubated with MTT solution (0.5 mg/ml) for 3 h,
and the precipitate of the reduced MTT was dissolved using DMSO for
5 min. Absorbance was measured in a multiplate reader (NovoStar,
LabTech) at wavelengths of 560 nm and 620 nm, and was quantified
using NovoStar Software for the different experimental conditions.
4.9. Live/dead assay
The protocol was followed as previously described (Araya et al.,
2014). Hippocampal neurons were incubated for 96 h with Aβ (1 μM),
vehicle control, M30, or a potent mitochondrial oxidative phosphor-
ylation uncoupler FCCP as a positive control for death. After the
treatment, neurons were washed with PBS (Gibco, USA) and then
treated with Calcein-AM and Ethidium homodimer-1 (EthD-1) for
30 min at 37 °C, as described by the manufacturer (Invitrogen,
Carlsbad, CA, USA). After a final wash with PBS, the EthD-1 emission
was detected at 635 nm and calcein at 515 nm in a multiplate reader
(Novostar). An increase in red fluorescence reflected an increase in
neuronal death, while an increment in the green signal indicated more
viable neurons.
Fig. 8. M30 decreased Aβ-induced mitochondrial dysfunction and cytotoxicity. (A) The data shows MTT reduction assays obtained in PC12 cells treated with Aβ
(1 μM) alone, FCCP (10 μM, positive control) and M30 (5 μM) with and without Aβ for 24 h. (B) Live/dead assay shows the effect in hippocampal neurons of Aβ
(1 μM, 96 h) and Aβ plus different concentrations of M30 (1, 10, 25 and 50 μM). (C) Live/dead assay shows that in hippocampal neurons, M30 (5 μM) only blocked
the toxicity induced by Aβ, but not FCCP. (D) M30 does not have intrinsic toxicity at 25 and 50 μM after 96 h treatment in hippocampal neurons. (E) Concentration
curve of M30 to achieve the reduction in Aβ toxicity after 96 h treatment. The results are from at least 4 independent measurements, *** p < .001.
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Fig. 9. Neuroprotective effects of M30 following injection of Aβ in the dentate gyrus. (A) Shows a mouse brain from the Allen Brain Institute showing the hippo-
campus in green. The image on the right shows the stereotaxic procedure, injecting the dentate gyrus (DG) of the left hemisphere with the vehicle, and the right DG
with Aβ-FAM (4 μl of Aβ 80 μM). (B) Coronal section of the injected DG showing Aβ-FAM after 1 day. (C) Coronal image showing DAPI staining after 2 weeks of Aβ-
FAM injection into the DG. (D, E) Quantification of Aβ-FAM from data in C for DAPI positive cells in the DG injected with the vehicle and Aβ-FAM respectively. (F)
The top images show Aβ-FAM (green) in the DG at 2 weeks post injection, while the bottom panel of images are of Aβ-FAM plus M30 (4 μl, 80 μM). (G) M30 protected
the DG from Aβ-FAM induced toxicity, shown by the increased presence of DAPI positive cells. (H, I) panel H is the quantification from data in G for DAPI positive
neurons in panel G. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
Fig. 10. M30 improves spatial learning and memory disruption by Aβ. (A) Scheme of the protocol for spatial learning and memory test. Saline, Aβ or Aβ+M30 were
injected bilaterally (see methods) into the DG and the Barnes Maze protocol was performed following 1 week. (B) Representative tracking of the animals around the
maze. (C, D) Plots showing the percentage of mice reaching the exit (before 3 min) and latency during the training days. Control (n= 6), Aβ (n= 7) and Aβ+M30
(n = 5). * denotes p < .05.
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4.10. Immunofluorescence
Hippocampal neurons plated in 35 mm dishes were washed in
phosphate-buffered saline (PBS; pH 7.4) and fixed with 4% paraf-
ormaldehyde for 15 min. Then, the neurons were washed again in PBS,
and the cells were permeabilized and blocked for 30 min with PBST
(triton X-100 0.1% in PBS) plus 10% bovine serum albumin.
Subsequently, cells were incubated with the following primary anti-
bodies between 16 and 24 h: anti-MAP2, 1:400 (Santa Cruz
Biotechnology), and anti-SV2 1:200 (Santa Cruz Biotechnology).
Secondary antibodies conjugated with FITC, Cy3, and/or Cy5 at a di-
lution of 1:200 for 2 h were used for fluorescent staining (Jackson
ImmunoResearch Laboratories, PA). Finally, samples were mounted in
fluorescent mounting medium (DAKO, CA, USA) and images were ob-
tained using a Nikon Eclipse confocal microscope (Nikon, Japan). The
immunoreactivity of the proteins was quantified at primary processes
with ImageJ software (NIH).
4.11. Dot blots and Western assays
For dot blots, the cells were lysed after treatment with a buffer
containing 0.5 mM EDTA, 140 mM NaCl, 0.5%Triton X-100, and
100 mM DTT. Equal amounts of proteins were added to a nitrocellulose
membrane and dried. Unspecific sites were blocked with 5% milk and
incubated with the primary anti-Aβ antibody (1:1000; Santa Cruz
Biotechnology). Then, secondary antibodies conjugated with horse-
radish peroxidase (1:5000 dilution; Santa Cruz Biotechnology) were
added and visualized with an ECL Plus Western Blotting Detection
System (PerkinElmer, MA, USA).
For western blots, equal amounts of proteins were separated using
10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis as
previously described (Peters et al., 2011). Protein bands were trans-
ferred onto nitrocellulose membranes, blocked with 5% milk, and in-
cubated with the primary anti-SV2 antibody (1:200; Developmental
Studies Hybridoma Bank, Iowa City, IA) for 24 h at 4 °C. A secondary
antibody conjugated with horseradish peroxidase (1:5000; Santa Cruz
Biotechnology) was incubated for 2 h and visualized with an ECL Plus
Western Blotting Detection System (PerkinElmer). The western blot for
β-actin, a house keeping marker, was used as a control for the amount
of SV2 loaded. This is particularly important to normalize signal var-
iations like in Fig. 7A.
4.12. Electrophysiology
Electrophysiological recordings were carried out using the patch-
clamp technique as previously described (Peters et al., 2015). Briefly,
after neuronal treatment for 48 h with Aβ (1 μM) or Aβ+M30 (1 μM),
the culture media was changed for an external solution containing (in
mM): 150 NaCl, 5.4 KCl, 2.0 CaCl2, 1.0 MgCl2, 10 glucose, and 10
HEPES (pH 7.4). The internal solution consisted of (in mM): 120 KCl,
2.0 MgCl2, 2 ATPeNa2, 10 BAPTA, 0.5 GTP, 10 HEPES (pH 7.4). The
holding potential was fixed at−60 mV, and postsynaptic currents were
acquired at 50 ms intervals using a Digidata 1200 board and the
pClamp10 software (Axon Instruments, Inc). Recording pipettes were
pulled from borosilicate glass (WPI, Sarasota, FL) on a horizontal puller
(Sutter Instruments, Novato, CA) having a resistance between 5 and
7 MΩ.
4.13. Stereotaxic injections
Stereotaxic injections were followed as previously described (Jean,
2015). Briefly, vehicle, Aβ-FAM (4 μl, 80 μM), or Aβ + M30 (4 μl,
80 μM) was injected into the DG of the hippocampus according to the
brain coordinates obtained from “The mouse brain in stereotaxic co-
ordinates”: AP -2.00 mm, ML±1.3 mm, DV -2.2 mm (Paxinos and
Franklin, 2001). For the cellular staining, injections of Aβ were made in
one hemisphere, while the other hemisphere was injected with
Aβ + M30 in order to reduce the dispersion between control and
treatment. After 2 weeks post-surgery, the mouse was anesthetized with
isoflurane and decapitated, and the brain removed and sliced with a
vibratome (Leica, Germany). Once the hippocampal slices were ob-
tained and fixed with 4% paraformaldehyde, the nucleus of the cells
was stained with DAPI and visualized with confocal microscopy. The
number or density of DAPI positive cells was analyzed and neuronal
death was reflected by a decrease in the number of DAPI positive cells
(Jean, 2015).
4.14. Memory and learning test
For memory and learning studies, male and female C57BL/J6 mice
(20–30 g; 6 to 12 months) were used in the Barnes Maze assay.
Basically, the study consists of a circular platform with a maximum of
20 holes around its circumference, in which visual cues, such as shapes
or patterns of colour, are placed around the table in plain sight of the
animal. Beneath one of the holes, there is an “escape box” to which the
mouse can access through the corresponding hole on the top of the
table. The model is based on the aversion of rodents to open spaces
which causes the mouse to take refuge in the escape box. A rodent after
4 or 5 trials will go directly to the escape hole without trying to escape
through the wrong holes. However, an impaired mouse will take much
longer to “learn” the location of the escape hole. To induce escape
behavior, we used a bright light that is aversive to rodents and increases
their motivation to go into a safe place. The escape box was maintained
at a fixed location for the duration of the training, which involved
multiple daily trials spread over several days.
4.15. Data analyses
The values are expressed as mean ± standard error mean
(± SEM). The nonlinear analysis was performed using Prism
(GraphPad Software, Inc). Statistical differences were determined using
Student's t-test, and data with more than two groups or factors were
analyzed by one-way ANOVA test followed by a Bonferroni post hoc
test. Values for *p < .05, **p < .01 and ***p < .001 were con-
sidered statistically significant. All the experiments were performed at
least in triplicate.
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